Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines

BACKGROUND: To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway. METHODS: SK-UT-1 and SK-UT-1B uLMS cells were treated with gemcitabine, docetaxel and dasatinib i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol Res Pract
Hlavní autoři: Lopez-Acevedo, Micael, Grace, Lisa, Teoh, Deanna, Whitaker, Regina, Adams, David J, Jia, Jingquan, Nixon, Andrew B, Secord, Angeles Alvarez
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877815/
https://ncbi.nlm.nih.gov/pubmed/27231555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2053-6844-1-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky